Alcon Acquires Neurotech Pharmaceuticals for USD 550 Million

Alcon has acquired Neurotech Pharmaceuticals for USD 550 million in cash, according to Ggba. The acquisition adds ENCELTO to Alcon.

Acquisition adds ENCELTO to Alcon

Ggba reported that ENCELTO is the only FDA-approved treatment for MacTel type 2. The reported transaction brings Neurotech Pharmaceuticals and ENCELTO into Alcon through a cash acquisition valued at USD 550 million.

The event is a notable portfolio development for pharmaceutical and biotech professionals who support ophthalmology-focused customers. Ggba identifies ENCELTO as the product added through the acquisition and MacTel type 2 as the condition associated with its FDA-approved status.

Reported transaction details

Ggba’s report centers on three core details: Alcon as the acquirer, Neurotech Pharmaceuticals as the acquired company, and USD 550 million in cash as the stated consideration. It also identifies ENCELTO as the only FDA-approved treatment for MacTel type 2.

For sales professionals, the acquisition places an FDA-approved treatment for MacTel type 2 within Alcon’s organization. The available report does not provide further details on commercial operations, customer communications, product stewardship, or organizational changes. Those topics are not addressed in the supplied report.

The reported deal therefore provides a clear update on ownership and portfolio composition. Alcon has acquired Neurotech Pharmaceuticals, and ENCELTO has been added to Alcon, according to Ggba.

Key reported details

• Alcon acquired Neurotech Pharmaceuticals.
• Ggba reported USD 550 million in cash consideration.
• The acquisition adds ENCELTO to Alcon.
• Ggba described ENCELTO as the only FDA-approved treatment for MacTel type 2.

Why the event matters

Acquisitions can change which organization represents a product and how portfolio conversations are framed with healthcare customers. In this case, the supplied report establishes that ENCELTO is now part of Alcon following the acquisition of Neurotech Pharmaceuticals.

Ggba’s report does not describe changes to ENCELTO’s indication or FDA-approved status. It identifies ENCELTO as the only FDA-approved treatment for MacTel type 2 and reports its addition to Alcon through the USD 550 million cash transaction.